CRESCENT BIOPHARMA, INC. 8-K

What Happened

• On February 26, 2026, Crescent Biopharma, Inc. (CBIO) filed a Current Report on Form 8-K (Item 2.02) to announce its financial results for the year ended December 31, 2025. The company furnished a press release with those results as Exhibit 99.1 to the 8-K. The filing was signed by CEO Joshua Brumm.

Key Details

• Filing date: February 26, 2026 (Form 8-K).
• Reporting period: Year ended December 31, 2025.
• Item reported: 2.02 (Results of Operations and Financial Condition) — press release furnished as Exhibit 99.1.
• Administrative exhibit: Inline XBRL cover page included (Exhibit 104); filing signed by CEO Joshua Brumm.

Why It Matters

• This 8-K is the company’s official disclosure of its 2025 annual financial results; investors should review the attached press release for revenue, net income (or loss), cash position, and any management commentary or guidance.
• Because the 8-K itself mainly references the press release, investors seeking specifics on earnings, revenue, expenses, or outlook should read Exhibit 99.1 or the company’s subsequent SEC filings for full financial statements and metrics.